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Recommended Citation: Terroba H, González A, Fielli M, et al. Strongyloides stercoralis hyperinfection and disseminated tuberculosis. Univ Louisville J Respir
Infect 2021; 5(1):Article 24.

Abstract
Asymptomatic infection due to Strongyloides stercoralis
may result in severe disease after treatment with systemic
steroids. A case of S. stercoralis hyperinfection in a woman
who was treated with systemic steroids for cerebral tuberculosis is reported. A 52-year-old female patient was admitted for a brain space–occupying lesion. A biopsy revealed
tuberculoid-like giant cells necrotizing granulomatous reaction. Antituberculous (anti-tb) therapy and corticosteroids
were started for suspected cerebral tuberculosis. Ten days
after admission, the patient developed respiratory failure. A

chest computed tomography showed multiple dense peripheral nodular infiltrates not seen at admission chest x-ray. Taking the patient’s epidemiological background into account,
ivermectin treatment was initiated, leading to clear improvement in her clinical condition. S. stercoralis was isolated from
a fecal sample. Ivermectin empirical treatment before initiation of high-dose corticosteroids in patients from endemic areas could be the best strategy for prevention of hyperinfection
by this parasite.

Introduction

orientation, and fever lasting for one month. She had
been previously evaluated in another institution for
several brain space–occupying lesions. A biopsy revealed tuberculoid-like giant cells necrotizing granulomatous reaction with multinucleated Langhans-type
cells. She was lost to follow-up, resulting in no treatment initiation.

Strongyloidiasis is a parasitosis widely distributed in
tropical and subtropical regions of the world. The infection prevalence is variable in Argentina, with a heterogeneous distribution; the northeast and northwest
are the two main endemic areas, with over 30 percent
of the population infected.[1, 2]
In immunosuppressed individuals, strongyloidiasis
can have potentially fatal complications, such as hyperinfection syndrome and disseminated strongyloidiasis.[3]
This article presents a S. stercoralis hyperinfection case
to highlight the importance of suspecting and preventing the presence of this infection in patients who are
due to receive immunosuppressive drugs, such as corticosteroids.

Case Description
A 52-year-old healthy female from Santiago del Estero was admitted to the hospital with aphasia, dis-
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At present admission, the vital signs were temperature 37.8 °C, arterial blood pressure 100/60 mmHg,
and heart rate 82 beats/minute. Physical examination revealed disorientation, ataxia, and mutism, but
there was no other abnormal finding. Our laboratory results reported no anemia, white blood cell elevation, or platelet count abnormality. A differential with
eosinophil count was not performed. No renal or hepatic function abnormalities were found. C-reactive protein (CRP) was 14 (normal range: 0–5 mg/L). A brain
computed tomography (CT) showed multiple supraand infratentorial isodense lesions, with mild periinjury edema and post-surgical changes at the biopsy
site. A cerebrospinal fluid exam showed normal glucose and proteins. The acid fast stain was negative.
Antituberculous (anti-tb) therapy and systemic corticosteroids were started for suspected cerebral tubercu-
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losis.
After ten days of treatment and slow improvement
of neurological symptoms, the patient developed diarrhea, persistent fever of 39 °C and hypoxemia. A
chest CT showed multiple dense peripheral nodular infiltrates in the upper lobes, middle lobe, and lingula, as
well as laminar bilateral pleural effusions. Piperacillintazobactam was started for hospital-acquired infection.
Furthermore, oral metronidazole and vancomycin for
Clostridium difficile (toxin A and B positive in stool sample) were started while anti-tb treatment was continued. Given the patient’s worsening respiratory status
(PaO2 /FiO2 142) and the persistence of diarrhea, a new
chest CT was obtained, which showed progression of
lung nodules and involvement of inferior lobes with
predominance of apical and posterior segments (Figure
1).
Taking the epidemiological background into consideration, as well as the clinical and radiological findings,
a S. stercoralis hyperinfection was suspected. Empirical treatment with ivermectin was started. Smears of
peripheral blood showed 38 percent eosinophils. Immunoglobulin E was 2,348 Ul/ml. The stool specimen
parasitological examination revealed the presence of
the nematode S. stercoralis.After starting treatment with
ivermectin, the patient´s clinical condition improved,
and the need for oxygen decreased. A bronchoscopy
was performed, and the bronchoalveolar lavage culture was positive for M. tuberculosis. A new CT showed
resolution of the infiltrates (Figure 2), and the patient
was discharged 30 days after admission with outpatient follow-up recommended.

Discussion
S. stercoralis can evolve over decades as a chronic parasitization in humans. Its cycle begins when the filariform larvae of the soil penetrate the skin and reach
the pulmonary alveoli through the bloodstream; from
there, they ascend through the tracheobronchial tree,
are swallowed, and reach the duodenum and jejunum,
where they mature to adult female worms. These then
lay eggs by parthenogenesis and give rise to rhabditiform larvae that are not infectious for humans. Some
of these larvae can transform into filariform larvae in
the intestine itself and auto-infect the host through the
colorectal mucous membrane.[4–5] Hyperinfection by
S. stercoralis can produce a severe clinical picture with
high mortality (30–60%). The manifestations of pulmonary strongyloidiasis occur as a result of two different situations: larval migration and hyperinfection.
Larval lung migration is part of the parasite’s ordinary
cycle and is generally asymptomatic. In a minority of
cases, larval migration triggers a marked hypersensitivity reaction that causes cough, dyspnea, chest pain,
and fever with pulmonary infiltrates associated with
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peripheral eosinophilia called Löffler’s syndrome. Perforation of the pulmonary alveoli causes small vessel
bleeding, exudation, and local inflammation. Many
parasites reach the adult state when they stay in the
lung for an extended period. Hyperinfection is characterized by excessive worm burden. The massive larval
invasion of the lung generates cough and hemoptysis
by the migration of the larvae from the capillary bed to
the alveoli and can even lead to diffuse alveolar hemorrhage. A patient will present with cough, fever and
dyspnea and may be in a potentially catastrophic condition. The absence of eosinophilia may indicate a significant alteration of the immune response and a worse
prognosis.[2–6] Chest images may show diffuse interstitial infiltrates, consolidation, or abscesses. When
the infection involves other organs besides the intestine and lung, such as the heart, liver, lymph nodes,
central nervous system, stomach, or skin, it is considered a disseminated form. There is a known association between S. stercoralis hyperinfection and secondary bacterial infections, usually related to Gramnegative rod bacteremia from injured intestinal mucous
membranes.[7, 8]
Corticosteroid use and HTLV-1 infection are the factors most associated with hyperinfection syndrome.[9]
Other predisposing conditions include neoplastic disease, chronic lung disease, autoimmune diseases,
transplantation, malnutrition, and immunosuppressive treatments. Corticosteroid therapy is associated
with two to three times the risk of triggering a chronic
asymptomatic infection with S. stercoralis to a severe
form of the disease. In addition, symptoms associated
with hyperinfection may relapse because of corticosteroid use (for cerebral tuberculosis in this case) and the
delay of effective therapy for strongyloidiasis.[10] One
of the explanations for corticosteroids inducing hyperinfection is acute suppression of eosinophilia and activation of lymphocytes. It has also been suggested that
corticosteroids could directly affect parasites by accelerating their transformation from filariform to rhabditiform larvae.[8]
In cases of hyperinfection and dissemination, the diagnosis is made by the direct examination of biological
samples: fecal matter, sputum, bronchial washing or
bronchoalveolar lavage.[6] Ivermectin is the treatment
of choice given that compared to albendazole and thiabendazole, ivermectin has a better safety profile.[11–
12]
In our case, the infection of brain tuberculosis demanding corticosteroid therapy resulted in S. stercoralis hyperinfection. Although some authors argue that the initial T cell response to M. tuberculosis infection may play
a role in S. stercoralis hyperinfection, we believe that in
our patient, treatment with steroids was the main cause
based on the temporal correlation between its initiation
and the manifestations of the disease.
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Figure 1. A chest computed tomography (CT), showing multiple dense peripheral nodular infiltrates in the upper andm iddle lobes and the lingula
ten days after admission.

Figure 2. A chest computed tomography (CT) showing resolution of peripheral nodular infiltrates 26 days after admission.
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Conclusion
S. stercoralis hyperinfection should be suspected in patients with acute pulmonary symptoms who receive
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immunosuppressive treatment and/or suffer from an
immunodeficiency illness in an endemic area of this
parasite.
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